DURECT Corporation (DRRX)
USD 0.6
(3.1%)
USD 0.6
(3.1%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 6.83 Million USD | -61.4% |
| 2022 | 17.69 Million USD | 47.19% |
| 2021 | 12.02 Million USD | -58.12% |
| 2020 | 28.7 Million USD | 12.92% |
| 2019 | 25.42 Million USD | 77.76% |
| 2018 | 14.3 Million USD | -66.38% |
| 2017 | 42.53 Million USD | 386.97% |
| 2016 | 8.73 Million USD | -42.6% |
| 2015 | 15.21 Million USD | 10.97% |
| 2014 | 13.71 Million USD | 30.76% |
| 2013 | 10.48 Million USD | -78.34% |
| 2012 | 48.41 Million USD | 68.26% |
| 2011 | 28.77 Million USD | 5.34% |
| 2010 | 27.31 Million USD | 44.15% |
| 2009 | 18.95 Million USD | -16.12% |
| 2008 | 22.59 Million USD | -17.7% |
| 2007 | 27.45 Million USD | 47.22% |
| 2006 | 18.64 Million USD | -27.61% |
| 2005 | 25.75 Million USD | 131.54% |
| 2004 | 11.12 Million USD | 18.24% |
| 2003 | 9.4 Million USD | 129.52% |
| 2002 | 4.09 Million USD | 31.13% |
| 2001 | 3.12 Million USD | 67.7% |
| 2000 | 1.86 Million USD | 420.67% |
| 1999 | 358 Thousand USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 1.53 Million USD | -23.52% |
| 2024 Q2 | 1.81 Million USD | 18.01% |
| 2023 Q2 | 1.72 Million USD | 3.36% |
| 2023 Q1 | 1.66 Million USD | -40.5% |
| 2023 Q3 | 1.43 Million USD | -16.84% |
| 2023 Q4 | 2.01 Million USD | 40.43% |
| 2023 FY | 6.83 Million USD | -61.4% |
| 2022 Q2 | 1.68 Million USD | 6.52% |
| 2022 FY | 17.69 Million USD | 47.19% |
| 2022 Q3 | 11.63 Million USD | 591.15% |
| 2022 Q4 | 2.8 Million USD | -75.93% |
| 2022 Q1 | 1.58 Million USD | -75.38% |
| 2021 Q2 | 1.94 Million USD | 4.52% |
| 2021 Q4 | 6.41 Million USD | 256.3% |
| 2021 Q1 | 1.86 Million USD | 3.97% |
| 2021 FY | 12.02 Million USD | -58.12% |
| 2021 Q3 | 1.8 Million USD | -7.36% |
| 2020 Q3 | 1.61 Million USD | -93.5% |
| 2020 Q4 | 1.78 Million USD | 10.57% |
| 2020 Q1 | 1.54 Million USD | -83.39% |
| 2020 FY | 28.7 Million USD | 12.92% |
| 2020 Q2 | 24.88 Million USD | 1512.44% |
| 2019 Q1 | 2.99 Million USD | 18.19% |
| 2019 Q3 | 10.03 Million USD | 222.99% |
| 2019 Q2 | 3.1 Million USD | 3.71% |
| 2019 FY | 25.42 Million USD | 77.76% |
| 2019 Q4 | 9.28 Million USD | -7.42% |
| 2018 Q4 | 2.53 Million USD | -64.43% |
| 2018 FY | 14.3 Million USD | -66.38% |
| 2018 Q3 | 7.12 Million USD | 205.88% |
| 2018 Q2 | 2.32 Million USD | 0.65% |
| 2018 Q1 | 2.31 Million USD | -87.48% |
| 2017 Q4 | 18.47 Million USD | 4.74% |
| 2017 FY | 42.53 Million USD | 386.97% |
| 2017 Q1 | 3.02 Million USD | 18.03% |
| 2017 Q2 | 3.39 Million USD | 12.27% |
| 2017 Q3 | 17.64 Million USD | 419.62% |
| 2016 Q4 | 2.56 Million USD | 63.92% |
| 2016 Q1 | 2.36 Million USD | -43.32% |
| 2016 Q2 | 2.24 Million USD | -5.16% |
| 2016 Q3 | 1.56 Million USD | -30.35% |
| 2016 FY | 8.73 Million USD | -42.6% |
| 2015 Q4 | 4.17 Million USD | 8.16% |
| 2015 Q3 | 3.85 Million USD | 12.87% |
| 2015 Q2 | 3.41 Million USD | -9.24% |
| 2015 Q1 | 3.76 Million USD | 22.54% |
| 2015 FY | 15.21 Million USD | 10.97% |
| 2014 Q3 | 1.92 Million USD | -44.96% |
| 2014 FY | 13.71 Million USD | 30.76% |
| 2014 Q1 | 5.23 Million USD | 60.63% |
| 2014 Q4 | 3.07 Million USD | 60.02% |
| 2014 Q2 | 3.49 Million USD | -33.27% |
| 2013 Q4 | 3.25 Million USD | 75.81% |
| 2013 Q3 | 1.85 Million USD | -35.83% |
| 2013 Q2 | 2.88 Million USD | 15.67% |
| 2013 Q1 | 2.49 Million USD | 12.19% |
| 2013 FY | 10.48 Million USD | -78.34% |
| 2012 FY | 48.41 Million USD | 68.26% |
| 2012 Q1 | 39.72 Million USD | 396.05% |
| 2012 Q2 | 3.67 Million USD | -90.74% |
| 2012 Q3 | 2.79 Million USD | -24.12% |
| 2012 Q4 | 2.22 Million USD | -20.32% |
| 2011 Q3 | 6.81 Million USD | 0.99% |
| 2011 FY | 28.77 Million USD | 5.34% |
| 2011 Q4 | 8 Million USD | 17.51% |
| 2011 Q1 | 7.2 Million USD | -1.58% |
| 2011 Q2 | 6.74 Million USD | -6.32% |
| 2010 Q4 | 7.31 Million USD | 0.85% |
| 2010 Q2 | 6.45 Million USD | 2.61% |
| 2010 Q3 | 7.25 Million USD | 12.48% |
| 2010 Q1 | 6.28 Million USD | 54.8% |
| 2010 FY | 27.31 Million USD | 44.15% |
| 2009 Q2 | 4.04 Million USD | -24.29% |
| 2009 Q3 | 5.54 Million USD | 37.23% |
| 2009 Q4 | 4.06 Million USD | -26.73% |
| 2009 FY | 18.95 Million USD | -16.12% |
| 2009 Q1 | 5.33 Million USD | -24.15% |
| 2008 Q2 | 5.32 Million USD | -5.25% |
| 2008 Q4 | 7.03 Million USD | 22.05% |
| 2008 Q3 | 5.76 Million USD | 8.33% |
| 2008 Q1 | 5.61 Million USD | -2.8% |
| 2008 FY | 22.59 Million USD | -17.7% |
| 2007 Q4 | 5.77 Million USD | 39.16% |
| 2007 Q3 | 4.15 Million USD | -67.19% |
| 2007 Q1 | 4.86 Million USD | 9.15% |
| 2007 Q2 | 12.65 Million USD | 160.05% |
| 2007 FY | 27.45 Million USD | 47.22% |
| 2006 FY | 18.64 Million USD | -27.61% |
| 2006 Q1 | 4.38 Million USD | -10.46% |
| 2006 Q2 | 5.33 Million USD | 21.82% |
| 2006 Q3 | 4.46 Million USD | -16.3% |
| 2006 Q4 | 4.45 Million USD | -0.22% |
| 2005 Q4 | 4.89 Million USD | -39.2% |
| 2005 Q2 | 8.13 Million USD | 73.61% |
| 2005 FY | 25.75 Million USD | 131.54% |
| 2005 Q1 | 4.68 Million USD | 37.29% |
| 2005 Q3 | 8.04 Million USD | -1.0% |
| 2004 FY | 11.12 Million USD | 18.24% |
| 2004 Q3 | 2.68 Million USD | 21.1% |
| 2004 Q1 | 2.82 Million USD | 12.04% |
| 2004 Q4 | 3.41 Million USD | 27.28% |
| 2004 Q2 | 2.21 Million USD | -21.52% |
| 2003 Q1 | 1.98 Million USD | 64.81% |
| 2003 FY | 9.4 Million USD | 129.52% |
| 2003 Q4 | 2.51 Million USD | 12.42% |
| 2003 Q3 | 2.23 Million USD | -16.02% |
| 2003 Q2 | 2.66 Million USD | 34.24% |
| 2002 Q3 | 1.06 Million USD | 7.6% |
| 2002 Q2 | 987 Thousand USD | 16.8% |
| 2002 Q1 | 845 Thousand USD | 13.27% |
| 2002 FY | 4.09 Million USD | 31.13% |
| 2002 Q4 | 1.2 Million USD | 13.47% |
| 2001 Q4 | 746 Thousand USD | -15.03% |
| 2001 Q3 | 878 Thousand USD | 23.14% |
| 2001 Q2 | 713 Thousand USD | -28.63% |
| 2001 Q1 | 999 Thousand USD | 1287.5% |
| 2001 FY | 3.12 Million USD | 67.7% |
| 2000 Q3 | 771 Thousand USD | 46.86% |
| 2000 Q1 | 541 Thousand USD | 0.0% |
| 2000 FY | 1.86 Million USD | 420.67% |
| 2000 Q2 | 525 Thousand USD | -2.96% |
| 2000 Q4 | 72 Thousand USD | -90.66% |
| 1999 FY | 358 Thousand USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| ANI Pharmaceuticals, Inc. | 305.3 Million USD | 97.763% |
| Aquestive Therapeutics, Inc. | 29.75 Million USD | 77.04% |
| Collegium Pharmaceutical, Inc. | 326.16 Million USD | 97.906% |
| Cosmos Health Inc. | 4.34 Million USD | -57.05% |
| Cyclo Therapeutics, Inc. | -2.41 Million USD | 383.423% |
| Esperion Therapeutics, Inc. | 73.06 Million USD | 90.651% |
| Cronos Group Inc. | 6.99 Million USD | 2.287% |
| Incannex Healthcare Limited | 12 Thousand USD | -56825.0% |
| Kala Pharmaceuticals, Inc. | -303 Thousand USD | 2354.455% |
| Lifecore Biomedical, Inc. | 41.85 Million USD | 83.677% |
| Regencell Bioscience Holdings Limited | -745.58 Thousand USD | 1016.19% |
| Sunshine Biopharma, Inc. | 8.33 Million USD | 18.085% |
| Sunshine Biopharma, Inc. | 8.33 Million USD | 18.085% |
| SCYNEXIS, Inc. | 124.51 Million USD | 94.514% |
| Safety Shot Inc | -74.45 Thousand USD | 9274.423% |
| Theratechnologies Inc. | 62.12 Million USD | 89.005% |
| Alpha Teknova, Inc. | 10.29 Million USD | 33.654% |
| Universe Pharmaceuticals INC | 10.07 Million USD | 32.218% |
| Pacira BioSciences, Inc. | 490.3 Million USD | 98.607% |
| Sonoma Pharmaceuticals, Inc. | 4.74 Million USD | -43.962% |
| Dynavax Technologies Corporation | 182.11 Million USD | 96.249% |
| Ironwood Pharmaceuticals, Inc. | 441.16 Million USD | 98.452% |
| Radius Health, Inc. | 307.71 Million USD | 97.78% |
| China SXT Pharmaceuticals, Inc. | 553.97 Thousand USD | -1133.097% |
| Alvotech | -69.42 Million USD | 109.84% |
| Intra-Cellular Therapies, Inc. | 430.62 Million USD | 98.414% |
| SIGA Technologies, Inc. | 122.09 Million USD | 94.405% |
| Shineco, Inc. | 882.16 Thousand USD | -674.342% |
| Silver Spike Investment Corp. | 8.1 Million USD | 15.694% |
| Journey Medical Corporation | 52.52 Million USD | 86.994% |
| Petros Pharmaceuticals, Inc. | 4.19 Million USD | -62.986% |
| Embecta Corp. | 749.9 Million USD | 99.089% |
| Harrow Health, Inc. | 90.55 Million USD | 92.456% |
| Procaps Group, S.A. | 239.56 Million USD | 97.149% |
| Biofrontera Inc. | 16.62 Million USD | 58.916% |
| PainReform Ltd. | -15 Thousand USD | 45640.0% |
| Supernus Pharmaceuticals, Inc. | 523.74 Million USD | 98.696% |
| OptiNose, Inc. | 62.35 Million USD | 89.045% |
| RedHill Biopharma Ltd. | 3.05 Million USD | -123.661% |
| Organogenesis Holdings Inc. | 309.79 Million USD | 97.795% |
| Cumberland Pharmaceuticals Inc. | 33.48 Million USD | 79.6% |
| ProPhase Labs, Inc. | 16.23 Million USD | 57.935% |
| Phibro Animal Health Corporation | 312.48 Million USD | 97.814% |
| Procaps Group S.A. | 239.56 Million USD | 97.149% |
| TherapeuticsMD, Inc. | 1.3 Million USD | -424.654% |
| Viatris Inc. | 6.43 Billion USD | 99.894% |
| Rockwell Medical, Inc. | 8.7 Million USD | 21.519% |
| Aytu BioPharma, Inc. | 54.58 Million USD | 87.486% |
| Tilray Brands, Inc. | 223.35 Million USD | 96.942% |
| PetIQ, Inc. | 252.74 Million USD | 97.297% |
| Talphera, Inc. | -4.89 Million USD | 239.551% |
| Neurocrine Biosciences, Inc. | 1.84 Billion USD | 99.63% |
| Alimera Sciences, Inc. | 61.17 Million USD | 88.833% |
| Assertio Holdings, Inc. | 125.04 Million USD | 94.537% |
| Shuttle Pharmaceuticals Holdings, Inc. | -6811.00 USD | 100393.643% |
| Avadel Pharmaceuticals plc | 27.11 Million USD | 74.809% |
| Hempacco Co., Inc. | -1.21 Million USD | 661.837% |
| Alvotech | -69.42 Million USD | 109.84% |
| Lantheus Holdings, Inc. | 709.54 Million USD | 99.037% |
| Kamada Ltd. | 52.59 Million USD | 87.012% |
| Currenc Group, Inc. | 17.35 Million USD | 60.643% |
| Indivior PLC | 907 Million USD | 99.247% |
| Evoke Pharma, Inc. | 4.97 Million USD | -37.203% |
| Flora Growth Corp. | 17.73 Million USD | 61.489% |
| Cyclo Therapeutics, Inc. | -2.41 Million USD | 383.423% |
| Evolus, Inc. | 140.52 Million USD | 95.139% |
| HUTCHMED (China) Limited | 453.55 Million USD | 98.494% |
| Amphastar Pharmaceuticals, Inc. | 343.96 Million USD | 98.014% |
| Akanda Corp. | 111.44 Thousand USD | -6029.261% |